Ascentage Pharma (AAPG) announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation by the Center for Drug ...

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

Ascentage Pharma Group International’s (NASDAQ:AAPG – Get Free Report) quiet period is set to expire on Wednesday, March 5th. Ascentage Pharma Group International had issued 7,325,000 shares in its ...

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $ ...

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related ...

Japan's Takeda (NYSE:TAK) holds a 7.7% stake in the company.Ascentage (AAPG) shares are also listed on the Hong Kong Stock Exchange. The shares closed at the ADS equivalent of US$20.34 on Jan. 17 ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...